JAK3 inhibitor suppresses multipotent ILC2s and attenuates steroid-resistant asthma
Science Advances · 22.12.2023 · 9 (51)
DOI: 10.1126/sciadv.adi3770 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 22.12.2023. Verfasst von Jihyun Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Asthma. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Steroids are the standard treatment for allergic airway inflammation in asthma, but steroid-refractory asthma poses a challenge. Group 2 innate lymphoid cells (ILC2s), such as T helper 2 (T H 2) cells, produce key asthma-related type 2 cytokines. Recent insights from mouse and human studies indicate a potential connection between ILC2s and steroid-resistant asthma. Here, we highlight that lung ILC2s, rather than T H 2 cells, can develop steroid resistance, allowing them to persist and maintain their disease-driving activity even during steroid treatment. The emergence of multipotent IL-5 + IL-13 + IL-17A + ILC2s is associated with steroid-resistant ILC2s. The Janus kinase 3 (JAK3)/signal transducer and activator of transcription (STAT) 3, 5, and 6 pathways contribute to the acquisition of steroid-resistant ILC2s. The JAK3 inhibitor reduces ILC2 survival, proliferation, and cytokine production in vitro and ameliorates ILC2-driven Alternaria -induced asthma. Furthermore, combining a JAK3 inhibitor with steroids results in the inhibition of steroid-resistant asthma. These findings suggest a potential therapeutic approach for addressing this challenging condition in chronic asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea.
- Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, South Korea.
- Department of Biological Sciences, SRC Center for Immune Research on Non-lymphoid Organs, Sungkyunkwan University, Suwon, South Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
- Department of Biological Sciences, Sungkyunkwan University, Suwon, South Korea.
- Department of Life Science, Multitasking Macrophage Research Center, Ewha Womans University, Seoul, South Korea.
ORCID-Profile: Jihyun Kim, Jongho Ham, Hye Ryun Kang, Yong-Soo Bae, TaeSoo Kim, Hye Young Kim
Zitieren
APA
Kim, J., Ham, J., Kang, H. R., Bae, Y. S., Kim, T., & Kim, H. Y. (2023). JAK3 inhibitor suppresses multipotent ILC2s and attenuates steroid-resistant asthma. Science Advances, 9(51). https://doi.org/10.1126/sciadv.adi3770
Vancouver
Kim J, Ham J, Kang HR, Bae YS, Kim T, Kim HY. JAK3 inhibitor suppresses multipotent ILC2s and attenuates steroid-resistant asthma. Science Advances. 2023;9(51). doi:10.1126/sciadv.adi3770
BibTeX
@article{Kim2023,
author = {Kim, Jihyun and Ham, Jongho and Kang, Hye Ryun and Bae, Yong-Soo and Kim, TaeSoo and Kim, Hye Young},
title = {JAK3 inhibitor suppresses multipotent ILC2s and attenuates steroid-resistant asthma},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {51},
doi = {10.1126/sciadv.adi3770}
}
EUVIMED